University of Oxford: Malaria, Falciparum trials

The registry lists 46 Malaria, Falciparum studies with University of Oxford as lead sponsor. 2 are open to participants now and 3 have results posted.

Early Phase 1 2Phase 1 22Phase 2 21Phase 3 7Phase 4 3No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• R21/MM Dosing, Presentations, and PreservativesNot yet recruitingNCT07194668Phase 4
• Mass Vaccine and Drug Administration, BangladeshRecruitingNCT06068530Phase 4
• A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UKTerminatedNCT05400746Early Phase 1Results posted
• Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai AdultsCompletedNCT05252845Phase 2Results posted
• Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and VietnamCompletedNCT03355664Phase 3Results posted
• A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-MActive, not recruitingNCT07183371Phase 2
• Dose Finding Trial of R21/Matrix-M in School ChildrenActive, not recruitingNCT07074665Phase 2
• A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)Active, not recruitingNCT06958198Phase 1
• Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M AdjuvantActive, not recruitingNCT06549257Phase 1/2
• A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™CompletedNCT06320535Phase 1
• A Study to Compare Two Dosing Regimens for a New Malaria VaccineActive, not recruitingNCT06141057Phase 1
• A Study to Assess the Safety and Effectiveness of Two Experimental Malaria VaccinesCompletedNCT05978037Phase 1/2
• A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.CompletedNCT05790889Phase 1/2
• A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK AdultsActive, not recruitingNCT05385471Early Phase 1
• A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21CompletedNCT05357560Phase 1
• Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in TanzaniaCompletedNCT04318002Phase 1
• Controlled Human Malaria Infection Transmission Model - Phase ASuspendedNCT04280692Phase 1/2
• Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.TerminatedNCT04271306Phase 1
• VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M VaccineTerminatedNCT04130282Phase 1
• Mass Screening and Treatment for Reduction of Falciparum MalariaCompletedNCT04093765Not applicable
• A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan AdultsTerminatedNCT03947190Phase 2
• A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)CompletedNCT03939104Phase 3
• A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.CompletedNCT03923725Phase 3
• Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina FasoCompletedNCT03896724Phase 1/2
• A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and InfantsCompletedNCT03580824Phase 1/2
• Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in TanzaniaCompletedNCT03435874Phase 1
• Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern MyanmarWithdrawnNCT02461186Phase 2/3
• A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)CompletedNCT02453308Phase 2/3
• Evaluating the Efficacy of Artesunate-mefloquine and the Relative Roles of Resistance Genetic MarkersCompletedNCT02427360
• Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum MalariaCompletedNCT02389439Phase 2
• A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,SCompletedNCT02252640Phase 1/2
• A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5CompletedNCT02181088Phase 1
• A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum MalariaCompletedNCT02044198Phase 1/2
• A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,SCompletedNCT01883609Phase 1/2
• Targeted Chemo-elimination (TCE) of MalariaCompletedNCT01872702Not applicable
• A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1CompletedNCT01739036Phase 1/2
• SPK Study in AfghanistanCompletedNCT01707199Not applicable
• A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine CandidatesCompletedNCT01623557Phase 1/2
• Tracking Resistance to Artemisinin (TRAC)CompletedNCT01350856Phase 4
• Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum MalariaCompletedNCT01115439
• A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum MalariaCompletedNCT00984763Phase 1/2
• Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western CambodiaWithdrawnNCT00936767Phase 2/3
• Evaluation of Volume Status, Haemodynamics and Microcirculatory Flow in Adult Patients With Severe Falciparum MalariaCompletedNCT00692627
• A Comparative Study of Artekin With Standard Malarial Treatment Regimes in AfghanistanCompletedNCT00682578Phase 3
• Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western CambodiaCompletedNCT00493363Not applicable
• Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost RegimenCompletedNCT00408668Phase 1/2